Sign In
Buy NPCE
$15.88
-0.410 (-2.52%)
At Close: Jun 03, 2026
Contrasting NeuroPace (NASDAQ:NPCE) & Integer (NYSE:ITGR)
02:17am, Sunday, 05'th Apr 2026
Integer (NYSE: ITGR - Get Free Report) and NeuroPace (NASDAQ: NPCE - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
12:31pm, Thursday, 02'nd Apr 2026
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
12:26pm, Thursday, 02'nd Apr 2026
NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
10:56am, Thursday, 02'nd Apr 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the posi
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages
04:43am, Wednesday, 01'st Apr 2026
NeuroPace, Inc. (NASDAQ: NPCE - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are covering the company, Marketbeat Ratings reports. One analyst has rat
NPCE RNS System Explained: Growth Drivers and Setup for 2026
12:41pm, Tuesday, 10'th Mar 2026
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
12:41pm, Tuesday, 10'th Mar 2026
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
12:27pm, Tuesday, 10'th Mar 2026
NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.
NeuroPace to Present at the Leerink Global Healthcare Conference
04:30pm, Thursday, 05'th Mar 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t
Why NeuroPace Stock Was Inching Higher on Wednesday
03:24pm, Wednesday, 04'th Mar 2026
The niche medical devices specialist published its latest quarterly and annual fundamentals. Led by its No.
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript
09:02pm, Tuesday, 03'rd Mar 2026
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates
06:35pm, Tuesday, 03'rd Mar 2026
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
04:05pm, Tuesday, 03'rd Mar 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:01am, Tuesday, 24'th Feb 2026
NeuroPace (NPCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
04:30pm, Friday, 20'th Feb 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financ
